☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
relapsing multiple sclerosis
Novartis Reports Results of Ofatumumab (OMB157) in P-III ASCLEPIOS Trials for Relapsing Multiple Sclerosis
August 6, 2020
Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis in Adults
September 12, 2019
Celgene Files NDA for Ozanimod to the US FDA for Relapsing Forms of Multiple Sclerosis (RMS)
March 26, 2019
FDA to Refuse Celgene for Filling Ozanimod's NDA for the Treatment of Relapsing Multiple Sclerosis
February 27, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.